{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:53:41Z","timestamp":1794416021448,"version":"4.9.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG3DA048386"],"award-info":[{"award-number":["UG3DA048386"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UH3DA047711"],"award-info":[{"award-number":["UH3DA047711"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.vaccine.2025.127488","type":"journal-article","created":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T15:23:08Z","timestamp":1755962588000},"page":"127488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pre-clinical characterization of virus-like particles as a platform for nanovaccines against heroin and oxycodone"],"prefix":"10.1016","volume":"62","author":[{"given":"Davide","family":"Tronconi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Marecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Robert W.","family":"Seaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Hannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima A.","family":"Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pravetoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.127488_bb0005","article-title":"Provisional drug overdose death counts","author":"Ahmad","year":"2025","journal-title":"National Center for Health Statistics"},{"key":"10.1016\/j.vaccine.2025.127488_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2023.110985","article-title":"Prevalence of fentanyl in methamphetamine and cocaine samples collected by community-based drug checking services","volume":"252","author":"Wagner","year":"2023","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"10.1016\/j.vaccine.2025.127488_bb0015","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.7326\/M23-2001","article-title":"Xylazine adulteration of the heroin\u2013fentanyl drug supply","volume":"176","author":"D\u2019Orazio","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2025.127488_bb0020","article-title":"\u201cDon't judge a book by its cover\u201d: a qualitative study of methadone patients' experiences of stigma","volume":"11","author":"Woo","year":"2017","journal-title":"Subst Abus"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1017\/jme.2023.73","article-title":"State-specific barriers to methadone for opioid use disorder treatment","volume":"51","author":"Russoniello","year":"2023","journal-title":"J Law, Med & Ethics"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0030","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/15332560802157065","article-title":"\u201cYou\u2019re nothing but a junkie\u201d: multiple experiences of stigma in an aging methadone maintenance population","volume":"8","author":"Conner","year":"2008","journal-title":"J Soc Work Pract Addict"},{"issue":"6","key":"10.1016\/j.vaccine.2025.127488_bb0035","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and Meta-analysis of randomised and observational studies","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127488_bb0040","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF02246290","article-title":"Effects of buprenorphine and methadone in methadone-maintained subjects","volume":"119","author":"Walsh","year":"1995","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0045","first-page":"105","article-title":"A protocol to switch high-dose, methadone-maintained subjects to buprenorphine","volume":"6","author":"Levin","year":"1997","journal-title":"Am J Addict"},{"key":"10.1016\/j.vaccine.2025.127488_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.06.001","article-title":"Development of vaccines to treat opioid use disorders and reduce incidence of overdose","volume":"158","author":"Pravetoni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127488_bb0055","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/13543784.2023.2173062","article-title":"Immunotherapeutic strategies for treating opioid use disorder and overdose","volume":"32","author":"Luba","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127488_bb0060","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/13543784.2023.2187286","article-title":"The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis","volume":"32","author":"Martinez","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127488_bb0065","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1124\/pr.117.013904","article-title":"Conjugate vaccine immunotherapy for substance use disorder","volume":"69","author":"Bremer","year":"2017","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0070","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/jpet.118.253674","article-title":"A fentanyl vaccine alters fentanyl distribution and protects against fentanyl-induced effects in mice and rats","volume":"368","author":"Raleigh","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0075","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"19","key":"10.1016\/j.vaccine.2025.127488_bb0080","doi-asserted-by":"crossref","first-page":"16584","DOI":"10.1021\/acsomega.2c00820","article-title":"Preclinical efficacy and selectivity of vaccines targeting fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in rats","volume":"7","author":"Baehr","year":"2022","journal-title":"ACS Omega"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127488_bb0085","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1021\/acsptsci.1c00260","article-title":"Efficacy and selectivity of monovalent and bivalent vaccination strategies to protect against exposure to Carfentanil, fentanyl, and their mixtures in rats","volume":"5","author":"Crouse","year":"2022","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0090","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1021\/acsptsci.3c00228","article-title":"Multivalent vaccination strategies protect against exposure to Polydrug opioid and stimulant mixtures in mice and rats","volume":"7","author":"Song","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127488_bb0095","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1124\/jpet.120.000014","article-title":"Combining a candidate vaccine for opioid use disorders with extended-release naltrexone increases protection against oxycodone-induced behavioral effects and toxicity","volume":"374","author":"Raleigh","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"10.1016\/j.vaccine.2025.127488_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184876","article-title":"Safety and efficacy of an oxycodone vaccine: addressing some of the unique considerations posed by opioid abuse","volume":"12","author":"Raleigh","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127488_bb0105","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/jm3013745","article-title":"Reduced Antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone Haptens","volume":"56","author":"Pravetoni","year":"2013","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.vaccine.2025.127488_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096547","article-title":"Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats","volume":"9","author":"Pravetoni","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127488_bb0115","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"31","key":"10.1016\/j.vaccine.2025.127488_bb0120","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1016\/j.vaccine.2012.04.101","article-title":"Co-Administration of Morphine and Oxycodone Vaccines Reduces the distribution of 6-Monoacetylmorphine and oxycodone to brain in rats","volume":"30","author":"Pravetoni","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0125","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1124\/jpet.117.247049","article-title":"Opioid dose- and route-dependent efficacy of oxycodone and heroin vaccines in rats","volume":"365","author":"Raleigh","year":"2018","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1021\/acsptsci.3c00228","article-title":"Multivalent vaccination strategies protect against exposure to Polydrug opioid and stimulant mixtures in mice and rats","volume":"7","author":"Song","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127488_bb0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41541-023-00697-9","article-title":"A TLR7\/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models","volume":"8","author":"Crouse","year":"2023","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2025.127488_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122758","article-title":"The immunological and pharmacokinetic evaluation of lipid-PLGA hybrid nanoparticle-based oxycodone vaccines","volume":"313","author":"Walter","year":"2025","journal-title":"Biomaterials"},{"issue":"39","key":"10.1016\/j.vaccine.2025.127488_bb0145","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1016\/j.vaccine.2014.07.011","article-title":"Safety and immunogenicity of a virus-like particle pandemic influenza a (H1N1) 2009 vaccine: results from a double-blinded, randomized phase I clinical trial in healthy Asian volunteers","volume":"32","author":"Low","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150146","article-title":"Antibody persistence in adults two years after vaccination with an H1N1 2009 pandemic influenza virus-like particle vaccine","volume":"11","author":"Valero-Pacheco","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2025.127488_bb0155","doi-asserted-by":"crossref","DOI":"10.2147\/IJWH.S50365","article-title":"Long-term efficacy and safety of human papillomavirus vaccination","author":"De Vincenzo","year":"2014","journal-title":"Int J Women's Health"},{"issue":"46","key":"10.1016\/j.vaccine.2025.127488_bb0160","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1016\/j.vaccine.2019.09.057","article-title":"Influenza a and B virus-like particles produced in mammalian cells are highly immunogenic and induce functional antibodies","volume":"37","author":"Buffin","year":"2019","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2025.127488_bb0165","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","article-title":"Virus-like particle vaccinology, from bench to bedside","volume":"19","author":"Mohsen","year":"2022","journal-title":"Cell Mol Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2025.127488_bb0170","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/eji.200526285","article-title":"A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase I safety and immunogenicity","volume":"35","author":"Maurer","year":"2005","journal-title":"Eur J Immunol"},{"issue":"16_suppl","key":"10.1016\/j.vaccine.2025.127488_bb0175","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1200\/jco.2005.23.16_suppl.1008","article-title":"A therapeutic vaccine for nicotine dependence: results of a phase I and a randomized phase II study","volume":"23","author":"Cornuz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127488_bb0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.vaccine.2023.12.077","article-title":"A bacteriophage virus-like particle vaccine against oxycodone elicits high-titer and long-lasting antibodies that sequester drug in the blood","volume":"42","author":"Romano","year":"2024","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2025.127488_bb0185","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/jm3013745","article-title":"Reduced Antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone Haptens","volume":"56","author":"Pravetoni","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.vaccine.2025.127488_bb0190","article-title":"A two-dose regimen of q\u03b2 virus-like particle-based vaccines elicit protective antibodies against heroin and fentanyl","author":"Romano","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0195","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1021\/acs.bioconjchem.3c00415","article-title":"Enhancing protective antibodies against opioids through antigen display on virus-like particles","volume":"35","author":"Shafieichaharberoud","year":"2024","journal-title":"Bioconjug Chem"},{"issue":"19","key":"10.1016\/j.vaccine.2025.127488_bb0200","doi-asserted-by":"crossref","first-page":"16584","DOI":"10.1021\/acsomega.2c00820","article-title":"Preclinical efficacy and selectivity of vaccines targeting fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in rats","volume":"7","author":"Baehr","year":"2022","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0205","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.intimp.2015.09.012","article-title":"Anti-nicotine vaccines: comparison of Adjuvanted CRM 197 and Qb-VLP conjugate formulations for immunogenicity and function in non-human Primates","volume":"29","author":"McCluskie","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2025.127488_bb0210","doi-asserted-by":"crossref","DOI":"10.1021\/acsnano.4c14369","article-title":"Substructure-specific antibodies against fentanyl derivatives","author":"Chapman","year":"2025","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127488_bb0215","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1021\/acschembio.1c00906","article-title":"Structure guided Design of Bacteriophage q\u03b2 Mutants as next generation carriers for conjugate vaccines","volume":"17","author":"Sungsuwan","year":"2022","journal-title":"ACS Chem Biol"},{"issue":"23","key":"10.1016\/j.vaccine.2025.127488_bb0220","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1016\/j.vaccine.2022.03.053","article-title":"Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder","volume":"40","author":"Hamid","year":"2022","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127488_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41541-025-01105-0","article-title":"Two doses of q\u03b2 virus like particle vaccines elicit protective antibodies against heroin and fentanyl","volume":"10","author":"Romano","year":"2025","journal-title":"NPJ Vaccines"},{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2025.127488_bb0230","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000052389","article-title":"Keyhole limpet hemocyanin: molecular structure of a potent marine immunoactivator","volume":"37","author":"Harris","year":"2000","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127488_bb0235","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1124\/jpet.111.189506","article-title":"An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia","volume":"341","author":"Pravetoni","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"23","key":"10.1016\/j.vaccine.2025.127488_bb0240","doi-asserted-by":"crossref","first-page":"14647","DOI":"10.1021\/acs.jmedchem.0c01042","article-title":"Therapeutic and prophylactic vaccines to counteract fentanyl use disorders and toxicity","volume":"63","author":"Robinson","year":"2020","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127488_bb0245","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1021\/acschembio.1c00906","article-title":"Structure guided Design of Bacteriophage q\u03b2 Mutants as next generation carriers for conjugate vaccines","volume":"17","author":"Sungsuwan","year":"2022","journal-title":"ACS Chem Biol"},{"issue":"2","key":"10.1016\/j.vaccine.2025.127488_bb0250","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.112.201194","article-title":"Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats","volume":"344","author":"Raleigh","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2025.127488_bb0255","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acs.molpharmaceut.8b00592","article-title":"Preclinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins","volume":"15","author":"Baruffaldi","year":"2018","journal-title":"Mol Pharm"},{"issue":"1","key":"10.1016\/j.vaccine.2025.127488_bb0260","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1021\/acs.molpharmaceut.0c00837","article-title":"Developing translational vaccines against heroin and fentanyl through investigation of adjuvants and stability","volume":"18","author":"Blake","year":"2021","journal-title":"Mol Pharm"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25007856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X25007856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T08:23:01Z","timestamp":1777537381000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X25007856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":52,"alternative-id":["S0264410X25007856"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127488","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-clinical characterization of virus-like particles as a platform for nanovaccines against heroin and oxycodone","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.127488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"127488"}}